Published in Leukemia on August 01, 2005
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene (2009) 1.18
The role of microenvironment in tumor angiogenesis. Genes Nutr (2008) 0.98
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol (2010) 0.95
Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia (2012) 0.91
Extraosseous (extramedullary) plasmacytomas: a clinicopathologic and immunophenotypic study of 32 Chinese cases. Diagn Pathol (2011) 0.90
Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. Korean J Hematol (2012) 0.90
Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma. Leukemia (2014) 0.83
Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Mol Cell Biol (2014) 0.82
A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. Haematologica (2014) 0.77
The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leuk Res (2016) 0.75
Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncol Lett (2017) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia (2007) 3.95
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc (1983) 3.22
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med (1997) 2.66
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia (2009) 2.28
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
"Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med (1982) 2.24
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol (2001) 2.10
Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med (1990) 2.05
Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 2.02
Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol (2001) 2.00
Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer (2000) 1.95
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia (2011) 1.92
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Primary renal non-Hodgkin's lymphoma. An unusual extranodal site. Cancer (1995) 1.82
True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood (1995) 1.81
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia (2007) 1.79
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Smoldering multiple myeloma. N Engl J Med (1980) 1.77
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med (1994) 1.73
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia (2006) 1.71
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood (1985) 1.67
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood (1996) 1.65
Treatment of the systemic capillary leak syndrome with terbutaline and theophylline. A case series. Ann Intern Med (1999) 1.63
Clinical significance of TP53 mutation in myeloma. Leukemia (2007) 1.62
Thalidomide in the treatment of plasma cell malignancies. J Clin Oncol (2001) 1.59
Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia (2008) 1.56
Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol (1996) 1.52
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia (2005) 1.51
Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med (1996) 1.51
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia (2011) 1.50
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine (1992) 1.47
Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med (2001) 1.47
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol (2001) 1.45
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia (2012) 1.41
Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol (2013) 1.41
Osseous Hodgkin disease. Cancer (1999) 1.41
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia (2006) 1.39
Factor-X deficiency in amyloidosis: a critical review. Am J Hematol (1981) 1.38
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia (2011) 1.38
Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia (2001) 1.36
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood (2000) 1.36
A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet (1998) 1.34
Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia (1996) 1.33
Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med (2001) 1.32
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia (2011) 1.31
Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc (2000) 1.30
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood (1986) 1.29
Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res (2000) 1.28
Treatment of newly diagnosed myeloma. Leukemia (2008) 1.27
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia (2012) 1.27
Response rates and survival in primary systemic amyloidosis. Blood (1991) 1.27
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia (2007) 1.25
Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood (1999) 1.24
Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol (1985) 1.24
Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am (1999) 1.23
Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry (1996) 1.22